Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | PYGO2 | Human | 1,2-dimethylhydrazine | increases expression | ISO | Pygo2 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of PYGO2 mRNA | CTD | PMID:22206623 | PYGO2 | Human | 17beta-estradiol | increases phosphorylation | EXP | | 6480464 | Estradiol results in increased phosphorylation of PYGO2 protein | CTD | PMID:27026707 | PYGO2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of PYGO2 mRNA | CTD | PMID:22298810 | PYGO2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PYGO2 mRNA | CTD | PMID:33387578 | PYGO2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Pygo2 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of PYGO2 mRNA | CTD | PMID:21570461 | PYGO2 | Human | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | Pygo2 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of PYGO2 mRNA | CTD | PMID:26251327 | PYGO2 | Human | 3,4-methylenedioxymethamphetamine | increases methylation | ISO | Pygo2 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in increased methylation of PYGO2 promoter | CTD | PMID:26251327 | PYGO2 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PYGO2 mRNA | CTD | PMID:28628672 | PYGO2 | Human | 5-aza-2'-deoxycytidine | increases expression | ISO | Pygo2 (Mus musculus) | 6480464 | Decitabine results in increased expression of PYGO2 mRNA | CTD | PMID:27915011 | PYGO2 | Human | acrolein | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of PYGO2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of PYGO2 mRNA | CTD | PMID:32699268 | PYGO2 | Human | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of PYGO2 mRNA | CTD | PMID:32763439 | PYGO2 | Human | allethrin | multiple interactions | ISO | Pygo2 (Rattus norvegicus) | 6480464 | [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PYGO2 mRNA and [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PYGO2 mRNA | CTD | PMID:33051911 and PMID:33396045 | PYGO2 | Human | alpha-pinene | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of PYGO2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of PYGO2 mRNA | CTD | PMID:32699268 | PYGO2 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of PYGO2 mRNA | CTD | PMID:33212167 | PYGO2 | Human | benzo[a]pyrene | increases expression | ISO | Pygo2 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of PYGO2 mRNA | CTD | PMID:22228805 | PYGO2 | Human | bisphenol A | increases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of PYGO2 mRNA | CTD | PMID:25181051 | PYGO2 | Human | bisphenol A | increases expression | ISO | Pygo2 (Mus musculus) | 6480464 | bisphenol A results in increased expression of PYGO2 mRNA | CTD | PMID:33221593 | PYGO2 | Human | bisphenol A | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PYGO2 mRNA | CTD | PMID:28628672 | PYGO2 | Human | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of PYGO2 mRNA | CTD | PMID:38568856 | PYGO2 | Human | caffeine | decreases phosphorylation | EXP | | 6480464 | Caffeine results in decreased phosphorylation of PYGO2 protein | CTD | PMID:35688186 | PYGO2 | Human | chlorpyrifos | increases expression | ISO | Pygo2 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of PYGO2 mRNA | CTD | PMID:37019170 | PYGO2 | Human | clofibrate | decreases expression | ISO | Pygo2 (Mus musculus) | 6480464 | Clofibrate results in decreased expression of PYGO2 mRNA | CTD | PMID:17585979 | PYGO2 | Human | cyhalothrin | multiple interactions | ISO | Pygo2 (Rattus norvegicus) | 6480464 | [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PYGO2 mRNA and [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PYGO2 mRNA | CTD | PMID:33051911 and PMID:33396045 | PYGO2 | Human | cypermethrin | multiple interactions | ISO | Pygo2 (Rattus norvegicus) | 6480464 | [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PYGO2 mRNA and [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PYGO2 mRNA | CTD | PMID:33051911 and PMID:33396045 | PYGO2 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PYGO2 mRNA | CTD | PMID:28628672 | PYGO2 | Human | Dibutyl phosphate | affects expression | EXP | | 6480464 | di-n-butylphosphoric acid affects the expression of PYGO2 mRNA | CTD | PMID:37042841 | PYGO2 | Human | dibutyl phthalate | decreases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | Dibutyl Phthalate results in decreased expression of PYGO2 mRNA | CTD | PMID:21266533 | PYGO2 | Human | fenthion | decreases expression | ISO | Pygo2 (Mus musculus) | 6480464 | Fenthion results in decreased expression of PYGO2 mRNA | CTD | PMID:34813904 | PYGO2 | Human | fenvalerate | multiple interactions | ISO | Pygo2 (Rattus norvegicus) | 6480464 | [Allethrins co-treated with cyhalothrin co-treated with cypermethrin co-treated with decamethrin co-treated with fenvalerate] results in decreased expression of PYGO2 mRNA and [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of PYGO2 mRNA | CTD | PMID:33051911 and PMID:33396045 | PYGO2 | Human | FR900359 | increases phosphorylation | EXP | | 6480464 | FR900359 results in increased phosphorylation of PYGO2 protein | CTD | PMID:37730182 | PYGO2 | Human | gentamycin | decreases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | Gentamicins results in decreased expression of PYGO2 mRNA | CTD | PMID:33387578 | PYGO2 | Human | glyphosate | affects expression | ISO | Pygo2 (Mus musculus) | 6480464 | Glyphosate affects the expression of PYGO2 mRNA | CTD | PMID:35489704 | PYGO2 | Human | indometacin | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PYGO2 mRNA | CTD | PMID:28628672 | PYGO2 | Human | methidathion | decreases expression | ISO | Pygo2 (Mus musculus) | 6480464 | methidathion results in decreased expression of PYGO2 mRNA | CTD | PMID:34813904 | PYGO2 | Human | N,N-dimethylaniline | decreases expression | EXP | | 6480464 | N and N-dimethylaniline analog results in decreased expression of PYGO2 protein | CTD | PMID:21291235 | PYGO2 | Human | nitrofen | increases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | nitrofen results in increased expression of PYGO2 mRNA | CTD | PMID:26720608 | PYGO2 | Human | nitrofen | decreases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | nitrofen results in decreased expression of PYGO2 mRNA | CTD | PMID:33484710 | PYGO2 | Human | ozone | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of PYGO2 mRNA more ... | CTD | PMID:32699268 | PYGO2 | Human | paracetamol | affects expression | ISO | Pygo2 (Mus musculus) | 6480464 | Acetaminophen affects the expression of PYGO2 mRNA | CTD | PMID:17562736 | PYGO2 | Human | potassium dichromate | increases expression | EXP | | 6480464 | Potassium Dichromate results in increased expression of PYGO2 protein | CTD | PMID:23718831 | PYGO2 | Human | resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of PYGO2 protein | CTD | PMID:21291235 | PYGO2 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of PYGO2 mRNA | CTD | PMID:23557933 | PYGO2 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of PYGO2 mRNA | CTD | PMID:38568856 | PYGO2 | Human | tetrachloromethane | increases expression | ISO | Pygo2 (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of PYGO2 mRNA | CTD | PMID:31919559 | PYGO2 | Human | thioacetamide | increases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of PYGO2 mRNA | CTD | PMID:34492290 | PYGO2 | Human | thiram | decreases expression | EXP | | 6480464 | Thiram results in decreased expression of PYGO2 mRNA | CTD | PMID:38568856 | PYGO2 | Human | urethane | decreases expression | EXP | | 6480464 | Urethane results in decreased expression of PYGO2 mRNA | CTD | PMID:28818685 | PYGO2 | Human | vinclozolin | decreases expression | ISO | Pygo2 (Rattus norvegicus) | 6480464 | vinclozolin results in decreased expression of PYGO2 mRNA | CTD | PMID:23034163 | PYGO2 | Human | vitamin E | increases expression | EXP | | 6480464 | Vitamin E results in increased expression of PYGO2 mRNA | CTD | PMID:19244175 | |